Sub menu

 
 

Note for guidance on start of shelf-life of the finished dosage form (Annex to note for guidance on the manufacture of the finished dosage form)

We have adopted this International Scientific Guideline - CPMP/QWP/072/96, EMEA/CVMP/453/01 

Last updated

 

About this guideline

Overseas effective date: December 2001

Note: Can be read in conjunction with the Note for guidance on manufacture of the finished dosage form (CPMP/QWP/486/95)

Categories: Quality | Manufacturing

                     Quality | Stability

TGA Annotations: Nil

 

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Topics

Help us improve the Therapeutic Goods Administration site